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Abstract
Background: Staphylococcus aureus, a gram-positive pathogen, causes many human infections. Methicillin-resistant
S. aureus (MRSA) is the most common drug-resistance bacteria. Nearly all MRSA bacteria are resistant to several
drugs. Specific antibodies are the main components of the host’s humoral immunity, and play a significant role in
the process of the host’s resistance to bacterial infection.
Results: A single-chain variable fragment (scFv) library was constructed using mRNA from the peripheral blood
mononuclear cells of S. aureus infected volunteers. After the scFv library DNA was transformed into Escherichia coli
TG1, ~1.7 × 107 independent clones with full-length scFv inserts. The scFv library was screened by phage display for
three rounds using S. aureus as an antigen. The single clones were chosen at random and the scFvs were expressed
for enzyme-linked immunosorbent assay (ELISA) assessment. Approximately 50 % of the clones were positive with
good binding activity to S. aureus. To improve the stability of scFvs, scFv-fragment crystallizable regions (-Fcs) were
constructed and expressed in E. coli DH5α. The expressed scFv-Fcs were purified and identified by western blot.
These antibodies were further characterized and analyzed for bioactivity. The results showed that the expression
level and folding of scFv-Fcs induced at 25 °C without isopropyl β-D-1-thiogalactopyranoside (IPTG) were higher
than that induced at 32 °C with 1.0 mmol/L IPTG. scFv-Fcs had good bioactivity and could specifically bind with S. aureus.
Conclusion: scFv-Fcs against S. aureus were successfully constructed and are good candidates for the development of
future adjunctive therapy for severe S. aureus infections.
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Background
Staphylococcus aureus, a gram-positive pathogen, causes
an large array of diverse human infections, ranging
from relatively minor skin and wound infections to
more serious life-threatening diseases, such as deep-
tissue infections, pneumonia, and bacteremia [1, 2].
Based on data from the U.S Centers for Disease Con-
trol and Prevention, S. aureus infection has been
deemed the most lethal of all infectious diseases. The
emergence and spread of multidrug-resistant strains
in communities and even in hospitals are making
therapeutic intervention increasingly difficult and ex-
pensive [3–5]. Meticillin-resistant S. aureus (MRSA) is
the most common drug-resistant bacteria and causes
clinical diseases such as skin infections, pneumonia,
and septicemia. Nearly all MRSAs are also multidrug
resistant and are not sensitive to β-lactam antibiotics,
such as penicillin and cephalosporins, or to chloromy-
cetin, lincomycin, aminoglycoside antibiotics, tetracyc-
line antibiotics, and macrolide antibiotics. Some S.
aureus are also not sensitive to vancomycin [6–9].
With only a few new antibiotics in development, con-
siderable interest and efforts have been directed to-
ward exploring active and passive immune-mediated
therapeutic approaches to prevent and treat staphylo-
coccal infections.
Specific antibodies are the main component of a host’s
humoral immunity, and play a significant role in the
process of creating a host’s resistance to bacterial infec-
tion. Antibodies can bind with the antigens of bacteria
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and kill or eliminate the bacteria through neutralization,
activating complements, promoting phagocytosis, and
antibody-dependent cellular cytotoxicity (ADCC). For
nearly 30 years, antibodies have gone through four
stages of development—murine antibodies, human-
mouse chimeric antibodies, humanized antibodies, and
fully human antibodies. Fully human antibodies are used
to reduce the rejection reaction when treating human
diseases [10, 11].
Traditional monoclonal antibodies were murine. If
used to treat human diseases, the human anti-mouse
antibody (HAMA) reaction would occur; therefore,
fully human antibodies were perfected to treat human
diseases. A fully human antibody is prepared in one
of two ways—using transgenic mice or constructing a
human phage single-chain variable fragment (scFv)
library. The molecular weight of the fully human anti-
body is too high to use phage display for selection.
scFv has the property of low molecular weight, which
is suitable for phage display, and has antigen-binding
properties; therefore, scFvs is the best block for con-
structing other types of antibodies. However, scFvs
are not stable and do not have the properties of frag-
ment crystallizable regions (Fcs), such as ADCC, so
Fcs were fused with scFvs, creating scFv-Fc, to in-
crease stability and recover Fc function.
In this study, an scFv library was constructed using
mRNA from peripheral blood mononuclear cells
(PBMCs) of volunteers infected with S. aureus and spe-
cific fully human scFv-Fvs against S. aureus were devel-
oped with the hope that an adjunctive therapy is
developed for severe S. aureus infections.
Methods
PBMCs of the five volunteers enrolled in this study
who were infected with S. aureus were used for the
construction of a scFv library. The criterion for
selecting volunteers was only that they were infected
with S. aureus, which was confirmed by tests from
the clinical laboratory in the first affiliated hospital
of Sichuan medical university, China. The experiment
was approved by the ethics committee of Sichuan
medical university (No. 5105025012142). All volun-
teers were adults and provided written informed
consent.
Construction of the scFv library
The scFv library was constructed by referring to pre-
vious reports by our research group [12]. Briefly,
PBMCs from volunteers infected with S. aureus were
isolated by Ficoll Paque Plus (Amersham Pharmacia
Biotech, Inc., Piscataway, NJ, USA) according to the
manufacturer’s instructions. mRNA was extracted
from the PBMCs using the Dynabeads mRNA
DIRECT kit (Invitrogen, USA) and was used to
synthesize full-length cDNA using the SMART cDNA
library construction kit (Clontech, USA). The variable
regions of heavy-chain (VH) and light-chain (VL) im-
munoglobulin (Ig) were amplified by four subsequent
polymerase chain reactions (PCRs) using a set of
primers and following Qing Yuan [12] and the VH
and VL gene repertoires were linked by overlapping
extension PCR [12].
The phage display vector pCANTAB-5E, Escheri-
chia coli strain TG1, and helper phage M13K07
(Amersham Pharmacia Biotech, Inc., Piscataway, NJ,
USA) were used to create the phage library. The scFv
library DNA (VH-linker-VL) and phagemid pCANTAB-5E
vector were digested with Sfi I and Not I. The
digested scFv fragments were inserted into the vector
to generate a scFv-gene III fusion library using T4
DNA ligase (New England BioLabs, UK) at 4.0 °C
overnight. The ligated products were transformed into
E. coli TG1 by electroporation and grown at 37 °C on
culture plates containing lysogeny broth (LB) medium
supplemented with 100 μg/mL ampicillin and 2.0 %
glucose. Thirty clones from the library were selected
at random and identified by PCR to estimate the pro-
portion of full-length scFv clones. The PCR products
were digested by BstN I for producing a fingerprint
map to estimate the diversity of scFvs. All clones on
the plates were scraped and suspended in LB contain-
ing 15 % glycerol.
Phage amplification
Eighty microliters of scraped bacterial cells or frozen
cell suspensions under glycerol were incubated in
40 mL LB containing 100 μg/mL ampicillin and
2.0 % glucose until the optical density at a wave-
length of 600 nm (OD600) = 0.2 while shaking at 37 °C.
The bacteria were collected by centrifugation and
suspended in 40 mL LB with ampicillin without glu-
cose. Approximately 6 × 109 transducing unit (TU) of
helper M13K07 (Amersham Pharmacia Biotech, Inc.,
Piscataway, NJ, USA) were added to each milliliter of
cell suspension, incubated for 15 min at 37 °C with-
out agitation, and incubated for another 2.0 h with
agitation. Kanamycin was added to obtain a final
concentration of 20 μg/mL, after which the cells
were incubated overnight at 32 °C. The phage was
subsequently precipitated with polyethylene glycol
(PEG)-NaCl (20 % PEG, 2.5 mol/L NaCl) and resus-
pended in 0.01 mol/L phosphate-buffered saline
(PBS) buffer.
Affinity selection
Immunotubes were coated with ~1.0 × 108 cfu/mL S.
aureus in coating buffer (0.1 mol/L Na2CO3/NaHCO3,
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pH 9.6) and left overnight at 4.0 °C; these were then se-
quentially blocked with 4.0 % fat-free milk for 1.0 h at
37 °C and gentle agitation. Approximately 1 × 1012 TU
from the freshly amplified scFv libraries were added to
the blocked immunotubes and incubated at room
temperature for 2.0 h. The immunotubes were rinsed 10
times with 0.01 mol/L PBST (0.05 % Tween-20 in
0.01 mol/L PBS) and 0.01 mol/L PBS separately, then
eluted with 0.1 mol/L glycine-HCl (pH 2.2) and ampli-
fied as above. In the second and third rounds of affinity
selection, 1 × 107 cfu/mL and 1 × 106 cfu/mL bacteria
antigen, respectively, were coated and the immunotubes
were washed separately 15 to 20 times with 0.01 mol/L
PBST and 0.01 mol/L PBS.
Phage enzyme-linked immunosorbent assay
Following affinity selection of the scFv library in three
rounds, individual clones were randomly chosen and
grown at 37 °C. The phage was amplified according
to the previously described protocols. The amplified
phage preparation (1012 TU) was blocked with 4.0 %
fat-free milk in 0.01 mol/L PBS for 30 min and added
to an immunoassay plate coated with S. aureus for
enzyme-linked immunosorbent assay (ELISA) and the
negative control (0.01 mol/L PBS) was set up. Plates
were incubated for 1.0 h, washed three times with
washing buffer PBST, and finally incubated with
horseradish peroxidase (HRP)-conjugated anti-M13
mouse monoclonal antibody (Amersham Pharmacia
Biotech, Inc., Piscataway, NJ, USA). The immunoreac-
tions were developed by incubating in TMB liquid
substrate (Sigma-Aldrich Company, Inc., St. Louis,
MO, USA) for 15 min. The reactions were stopped
by adding 2.0 mol/L H2SO4. Absorbance at 450 nm
was recorded and used to select the phage that
expressed scFv for recognizing the target antigens.
Construction and expression of scFv-Fcs
pLZ16 was designed based on pUC vector for soluble
scFv-Fc antibody production by introducing leader
peptide-encoding sequencing (PhoA leader), cloning
sites (HindIII, BamHI, NotI) and FLAG tag. The Fc
was inserted into the plasmid (Fig. 1). The selected
scFvs with good binding activity and specificity were
ligated with the pLZ16 vector and transformed into
DH5α cells of E. coli. The positive clones were cul-
tured to OD600 = 0.5 at 37 °C in LB with 100 μg/mL
ampicillin, 2.0 % glucose (LBAG) and then centri-
fuged at 5000 r/min for 10 min. One of the following
two techniques was used to induce scFv-Fcs expres-
sion. One technique was to resuspend the pellets with
LBA containing 2.0 mmol/L MgCl2 and culture at
25 °C for 50 h [13]. The other was to resuspend the
pellets with LBA and 1.0 mmol/L IPTG and culture
at 32 °C for 5.0 h. After centrifugation, the pellet was
collected and resuspended in 0.01 mol/L PBS. The
suspended cells were sonicated and centrifuged, and
the supernatant was detected by ELISA and western
blot.
scFv-Fc functionality
The binding activity of and specificity of scFv-Fcs to S.
aureus was tested by dot blot and ELISA using the anti-
human IgG1 Fc antibody. Briefly, S. aureus, S. albus, S.
citreus, Salmonella typhi, Bacillus anthracis,, Shigella
Castellani, Proteusbacillus vulgaris, Monilia albican, α-
hemolytic streptococcus and β-hemolytic streptococcus
was suspended in Na2CO3/NaHCO3 coating buffer at a
concentration of 107 cfu/mL and the ELSIA plates were
coated at 4.0 °C overnight or the nitrocellulose mem-
brane was dotted for dot blot analysis. The scFv-Fcs
were purified and 1 μg/mL purified scFv-Fcs were used
as first antibody and the anti-human IgG1 Fc antibody
was used as second antibody for test. The dot blot
immunoreactions was developed by chemiluminscence
and the ELISA immunoreactions was developed by TMB
substrate.
The binding activity of scFv-Fcs were also analyzed by
BIAcore (BLITZ). The scFv-Fcs were immobilized on the
anti-hIgG Fc capture (AHC) biosensor. Then the S. aureus
with different concentration (1 × 107 cfu/mL, 2 × 107 cfu/
mL, 4 × 107 cfu/mL) were added and the association and
dissociation of scFv-Fcs and S. aureus were detected. The
0.01 mol/L PBS were used as control.
The opsonization of scFv-Fcs was researched by test-
ing the phagocytosis of antibody-opsonized pathogens.
The peritoneal macrophages of mice were isolated. The
Fig. 1 Plasmid map of pLZ16. The vector was constructed based on
the pUC vector and used for soluble single-chain variable fragment-
fragment crystallizable region (scFv-Fc) production
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Fig. 2 Amplification of VH, Vκ, and Vλ gene repertoires. Lane M: DNA Marker II (Tiangen, CN). The expected size of the amplified VH and VL
(including Vκ and Vλ) was ~350 bp. A part of amplified VH, Vκ, and Vλ were shown in Fig. 2
Fig. 3 a Thirty clones were chosen randomly from the single-chain variable fragment (scFv) library and the positive clones inserted into full scFv
genes were identified by polymerase chain reaction (PCR). Lane M: 2000 bp DNA Marker (TaKaRa, JP). Lanes 1–30: amplified scFvs from different
clones randomly picked. b PCR products of scFvs were digested by BstN I. 2000 bp DNA Marker (TaKaRa, JP). Lane M: 2000 bp DNA Marker
(TaKaRa, JP). Lanes 1–30: Fingerprints of scFvs digested by BstN I
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macrophages and S. aureus (1 × 107 cfu) was mixed at
the ratio 1:20 in RPMI-1640 medium containing 10 %
fetal calf serum (FCS). Ten microliter of scFv-Fc
(100 μg/mL) was added into the mixture and incu-
bated at 37 °C for 2 h with gentle agitation. The
mouse IgG1 was used as control and each group was
repeat for three times. Then the 200 μL of mixture
was spread the LB plates for overnight culture. The
following day, the clone numbers were calculated.
Statistical method
Background noise correction was performed from ELISA
by subtracting the absorbance. All the data were repeated
for three times and the data sets the mean and the stand-
ard error were calculated. Data were presented as means
± SEM. Differences between groups were determined by
the two-tailed t-test. P < 0.05 was considered statistically
significant. *p < 0.05, **P < 0.01, ***P < 0.001.
Results and discussion
Construction of the scFv library
mRNA was extracted from PBMCs of volunteers in-
fected S. aureus. The quality of the mRNA was the key
to synthesize the full-length cDNA. The integrity of the
extracted mRNA was determined by testing the OD260/
OD280 and electrophoresis. The synthesized ds cDNA
appeared as a smear of from 0.1 to 8.0 kb on the gel and
the size of distribution, yield, and intensity of cDNA
were satisfied (data not shown). The full-length cDNA
was used as a template to amplify the regions of VH and
VL, including Vκ and Vλ. The VH, Vκ, and Vλ gene reper-
toires were amplified with 42, 16, and 18 optimized pri-
mer sets, respectively. Nearly all PCR reactions were
effective and the correct PCR products were obtained
from the gel picture; the expected size of the amplified
VH and VL (including Vκ and Vλ) was ~350 bp. A part of
amplified VH, Vκ, and Vλ were shown in Fig. 2. The VH-
linker gene and VL-linker gene repertories were amplified
Fig. 4 Amino acid sequences of 10 clones which were randomly picked from the library and analyzed by DNA sequence
Fig. 5 The specificity of selected single-chain variable fragment (scFvs) detected by enzyme-linked immunosorbent assay. Number 15 and 16
were negative controls
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and the VH-linker-VL gene repertories (750 bp) were ob-
tained by overlapping extension PCR. The DNA library of
human scFvs was developed.
The DNA of the scFv library was ligated with phagemid
vector pCANTAB-5E and transformed into TG1 cells of E.
coli. Thirty clones were randomly chosen and the inserted
scFvs were identified by PCR. The results showed that all
clones contained full-length scFv genes. By BstN I digestion
of the scFv DNA, the fingerprint maps showed that almost
all scFvs were different (Fig. 3); For further analysis of the
diversity of the library, the 10 clones were picked randomly
for sequencing. The results showed that the sequences of
those scFvs were diverse (Fig. 4). The library was estimated
to contain 1.7 × 107 unique scFv members.
Affinity selection
The phage library was amplified and for each round of af-
finity selection, ~1012 TU freshly amplified scFv antibody
library were used for screening. Approximately 1.1 × 106,
3.1 × 106, and 1.2 × 107 phages were recovered after the
first, second, and third cycles, respectively. Phage pools
before and after each round of affinity selection were
tested by ELISA, which was performed by using the anti-
M13 HRP-conjugated secondary antibody. The phage pool
before affinity selection had no signal with the antigen,
but after three rounds of screening, there was strong bind-
ing activity between the library phage and antigen (data
not shown). Hundreds of clones were randomly chosen
from the phage pool after three rounds of affinity selec-
tion. The phages amplified from those clones were tested
by ELISA and about 50 % showed positive whose absorb-
ance of OD450 was two-fold those of the negative controls.
scFv specificity test
From the hundreds of clones those with higher absorb-
ance had better binding activity to the antigen and were
selected for testing scFv specificity. The S. aureus, S. albus,
S. citreus, S. typhi, B. anthracis, S. castellani, P. vulgaris,
M. albicans, α-H.streptococcus and β-H. streptococcus (1 ×
107 cfu/ml) were diluted in coating buffer and coated in
Fig. 6 a Constructed scFv-Fcs (S78, S128, S117, S182) were amplified and their sizes were ~1.5 kb. Lane M: 2000 bp DNA Marker (TaKaRa, JP).
b Expression level of scFv-Fcs (S78, S128, S117, S182) expressed at 25 °C and 32 °C, respectively, were tested by enzyme-linked immunosorbent assay
Fig. 7 a The scFv-Fcs (S78, S117) expressed at 25 °C and 32 °C respectively were purified and run SDS-PAGE. Lane M: prestained protein ladder
(Fermentas, USA); b The scFv-Fcs (S78, S128, S117, S182) were identified by western blot. Lane M: prestained protein ladder (Fermentas, USA)
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wells of ELISA plates at 4.0 °C overnight. The ELISA re-
sults showed that 14 clones had good specificity with S.
aureus and no binding reaction with the control bacteria
(Fig. 5). Number 15 and 16 (0.01 mol/L PBS was added,
not scFvs) were used as the negative controls. Each test
was repeated for three times, the value of the blank was
removed, and the standard errors were calculated. The
scFvs with better binding activity and specificity (S78,
S117, S128, S182) were inserted into the pLZ16 vector
with human IgG1 Fc.
Construction and expression of scFv-Fcs
To overcome the instability of scFvs, scFv-Fcs were con-
structed. The Fc region comprises the CH2 and CH3 do-
mains and the hinge region of the human IgG1. The hinge
serves as a flexible spacer between the two parts of the Fc-
fusion protein, allowing each part of the molecule to func-
tion independently. After transformation, the clones were
identified by PCR amplification. The results showed that
the bands at 1.5 kb were amplified (Fig. 6a). The sequen-
cing results showed that the scFv-Fcs were correct. Next,
the scFv-Fcs were induced to express at 25 °C for 50 h
without IPTG or 32 °C for 5.0 h with 1.0 mmol/L IPTG.
The expressed scFv-Fcs were coated on the ELISA plates
and detected with goat anti-human IgG1 Fc HRP-
conjugated antibody. The results showed that OD450 of
scFv-Fcs expressed at 25 °C was higher than that
expressed at 32 °C (Fig. 6b). The positive results of detec-
tion with human IgG1 Fc HRP-conjugated antibody
showed that the Fc regions were successfully fused into
scFv. The expressed scFv-Fc (S78, S117) under the two
conditions were purified. From sodium dodecyl sulfate
polyacrylamide gel electrophoresis staining (SDS-PAGE)
(Fig. 7a), the scFv-Fcs was pure and not degraded after
50 h expression at lower temperatures (25 °C). The lower
temperature will degrade the aggregation of expressed
protein and stabilize the bioactivity of scFv-Fc. MgCl2 was
added to the medium to maintain the cell wall. Later, the
expressed scFv-Fcs (S78, S117, S128, S182) at 25 °C were
detected by western blot with the anti-FLAG HRP-
conjugated antibody and a single band of ~67 kDa ap-
peared (Fig. 7b). Based on this, it was concluded that a
lower temperature was beneficial to the expression and
folding of scFv-Fcs and that the system used is suitable for
the production of Fc-fused antibody fragments.
scFv-Fc functionality
The dot blot results showed that the scFv-Fcs had good
binding activity with the S. aureus using the goat anti-
human IgG1 Fc HRP-conjugated antibody (Fig. 8a). In
addition, the specificity of scFv-Fcs remained and had no
cross reaction with S. aureus, S. albus, S. citreus, S. typhi,
B. anthracis, S. castellani, P. vulgaris, M. albicans, α-H.
streptococcus or β-H streptococcus (Fig. 8b). The BIAcore
(BLITZ) results also showed that the scFv-Fcs (S78,
S117, S128, S182) could bind S. aureus well (Data not
shown). The real-time association and dissociation of
S117 and S. aureus were showed in Fig. 9, and the
Fig. 8 a Binding activity of scFv-Fcs (S78, S128, S117, S182) and S. aureus were detected by dot blot. The immunoreactions was developed by
chemiluminscence (b). Detection of the specificity of scFv-Fcs (S78, S128, S117, S182) by enzyme-linked immunosorbent assay
Fig. 9 Analysis of the association and dissociation of S117 and S. aureus. The S117 was immobilized on AHC biosensor, the different concentration of
S. aureus were tested. (run1: 1 × 107 cfu/mL, run 2: 2 × 107 cfu/mL, run 3: 4 × 107 cfu/mL)
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equilibrium dissociation constant (KD), the rate con-
stants for association (ka) and dissociation (kd) between
S. aureus and selected scFv-Fcs were listed in Table 1,
which were determined by BIAcore (BLITZ).
The opsonization of scFv-Fcs was detected. Com-
pared with mouse IgG controls, the plates spread
with the mixture containing scFv-Fc (S78, S117) had
less clones (Table 2) and it has statistically significant
for S78 (P < 0.01) and S117 (P < 0.001). The results
showed the scFv-Fcs (S78, S117) against S. aureus could
play the role of opsonization, and promoting the function
of phagocytosis of macrophage.
Discussion
Commercial murine IgG against S. aureus has been used
in research but no fully human antibody against S. aureus
has been commercially available for treatment of the in-
fection of S. aureus. Our scFv-Fc against S. aureus was a
fully human antibody, and the affinity of scFv was not
evolved in vivo; therefore, after the functional scFv-Fc was
selected, the affinity of scFv-Fc will be improved by affinity
maturation in vitro and the antigenic determinant of S.
aureus also will be researched. We hope to establish an
adjunctive therapy for severe S. aureus infections using
those antibodies.
scFv comprised only Ig VH and VL connected by a sol-
uble and flexible oligopeptide. scFv use is easy for the de-
sign and construction of a phage display antibody library,
and phage display technology makes possible the direct
isolation of monovalent scFv antibody fragments; however,
scFv has disadvantages of being unstable, having a short
serum half-life, and lacking avidity because of monovalent
binding, all of which could limit its effectiveness. Reducing
these disadvantages would be useful in making scFv more
successful as an antibody. The scFv-Fc format has certain
properties of IgGs, such as bivalency, tag-free detection,
and Fc-mediated effector functions. Moreover, scFv-Fc
antibodies have been successfully used to neutralize viral,
bacterial, and fungal pathogens in vitro and in vivo, which
suggests its potential uses in therapy [14–16].
In this study, the scFv against S aureus was screened
and merged with Fc. The scFv-Fc was expressed with the
vector pLZ16 and the better expression condition was in-
cubated at 25 °C for 50 h without IPTG. According to
Hiroyoshi (2008) [13], optimum conditions were estab-
lished for bacterial cultivation and protein expression, util-
izing an unusually long cultivation time (>50 h), very low
temperature (25 °C), and no IPTG, thereby leading to the
production and extracellular secretion of fragment
antigen-binding (Fab) proteins in a high-yield using the
vector pComb43C9 with lactose promoter.
Based on the report of Hiroyoshi [13], the vector
pLZ16 was designed in this study for expressing the
soluble scFv-Fc antibody. The results showed that the
overall gene expression level under the conditions of 25 °C
for 50 h and without IPTG induction was higher than the
expression under the conditions of 32 °C for 5.0 h with
IPTG. The production yield of the functional scFv-Fc at
25 °C was highly dependent on the following points: (1)
freshness of a single colony of the phagemid-harboring E.
coli cells; (2) temperature controls, including pre-warming
of the culture medium in the inoculation steps; and (3)
medium exchange to one with no glucose at the induction
step for protein expression [13].
Another study reported that auto-induction without
IPTG allows efficient screening many clones in parallel
for expression and solubility, as cultures need only to be
inoculated and grown to saturation, and yields of target
protein are typically several-fold higher than that ob-
tained by conventional IPTG induction [17].
The expressed and purified scFv-Fcs have good bio-
activity and specificity with S. aureus. In subsequent
studies, the antigenic determinant mechanisms of action
will be researched.
Conclusions
In this work, a human scFv library with a volume of
1.7 × 107 was constructed. From the library, specific
scFvs against S. aureus were selected using three rounds
of phage display. The scFv-Fcs with stable structure de-
veloped and expressed in E. coli DH5α, and the suitable
Table 1 The kinetic constants determined by BIAcore (BLITZ)
analysis for scFvs
scFv ka (1/Ms) kd (1/s) kd/ka(KD, M)
S78 4.937e4 5.731e-4 1.161e-8
S128 2.123e4 8.231e-4 3.877e-8
S117 5.539e5 4.804e-4 8.673e-9
S182 2.213e4 7.648e-4 3.456e-8
Table 2 Test of the opsonization of scFv-Fcs
clones clones
S. aureus +macrophage + S78 (42 ± 5) × 104 ** S. aureus +macrophage + IgG (78 ± 7) × 104
S. aureus +macrophage + S128 (62 ± 6) × 104 S.aureus +macrophage (82 ± 8) × 104
S. aureus +macrophage + S117 (26 ± 5)104***
S. aureus +macrophage + S182 (56 ± 6) × 104
**P <0.01, ***P <0.001
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expression system induced at 25 °C was beneficial for
the correct folding of scFv-Fcs. The purified scFv-Fcs
also had the functionality of good binding activity and
specificity to S. aureus. These antibodies could be used
as candidates for the development of future adjunctive
therapy for severe S. aureus infections.
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